NYSE:PFE - Pfizer Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $37.53 +0.01 (+0.03 %) (As of 07/15/2018 04:00 PM ET)Previous Close$37.53Today's Range$37.22 - $37.5952-Week Range$32.32 - $39.43Volume14.45 million shsAverage Volume19.76 million shsMarket Capitalization$223.41 billionP/E Ratio13.75Dividend Yield3.62%Beta0.93 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Receive PFE News and Ratings via Email Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNYSE:PFE CUSIP71708110 Webwww.pfizer.com Phone212-733-2323 Debt Debt-to-Equity Ratio0.45 Current Ratio1.27 Quick Ratio0.98 Price-To-Earnings Trailing P/E Ratio13.75 Forward P/E Ratio12.68 P/E Growth1.86 Sales & Book Value Annual Sales$52.55 billion Price / Sales4.25 Cash Flow$3.7493 per share Price / Cash10.01 Book Value$12.02 per share Price / Book3.12 Profitability EPS (Most Recent Fiscal Year)$2.65 Net Income$21.31 billion Net Margins41.29% Return on Equity25.29% Return on Assets9.78% Miscellaneous Employees90,200 Outstanding Shares5,952,870,000Market Cap$223,411.03 Pfizer (NYSE:PFE) Frequently Asked Questions What is Pfizer's stock symbol? Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE." How often does Pfizer pay dividends? What is the dividend yield for Pfizer? Pfizer announced a quarterly dividend on Thursday, June 28th. Shareholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a yield of 3.62%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History. How will Pfizer's stock buyback program work? Pfizer announced that its board has authorized a stock repurchase program on Tuesday, December 19th 2017, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's board believes its stock is undervalued. How were Pfizer's earnings last quarter? Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to analyst estimates of $13.14 billion. Pfizer had a net margin of 41.29% and a return on equity of 25.29%. The business's quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.69 EPS. View Pfizer's Earnings History. When is Pfizer's next earnings date? Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer. What guidance has Pfizer issued on next quarter's earnings? Pfizer issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion. What price target have analysts set for PFE? 21 brokers have issued 1 year price objectives for Pfizer's stock. Their predictions range from $36.00 to $45.00. On average, they expect Pfizer's share price to reach $40.4167 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Ratings for Pfizer. What is the consensus analysts' recommendation for Pfizer? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Are investors shorting Pfizer? Pfizer saw a decrease in short interest in June. As of June 29th, there was short interest totalling 59,174,572 shares, a decrease of 8.5% from the June 15th total of 64,685,349 shares. Based on an average daily trading volume, of 21,034,138 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.0% of the shares of the company are sold short. View Pfizer's Current Options Chain. Who are some of Pfizer's key competitors? Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG). Who are Pfizer's key executives? Pfizer's management team includes the folowing people: Mr. Ian C. Read, Chairman & CEO (Age 64)Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53) Has Pfizer been receiving favorable news coverage? Press coverage about PFE stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pfizer earned a news sentiment score of 0.07 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are Pfizer's major shareholders? Pfizer's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.66%), Hexavest Inc. (0.10%), NN Investment Partners Holdings N.V. (0.09%), Swedbank (0.06%), Gateway Investment Advisers LLC (0.05%) and Hamlin Capital Management LLC (0.05%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer. Which major investors are selling Pfizer stock? PFE stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Swedbank, KAMES CAPITAL plc, Gateway Investment Advisers LLC, Manning & Napier Group LLC, Hamlin Capital Management LLC, BLB&B Advisors LLC and Fjarde AP Fonden Fourth Swedish National Pension Fund. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer. Which major investors are buying Pfizer stock? PFE stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, DnB Asset Management AS, Pennsylvania Trust Co, Caledonia Investments PLC, Xact Kapitalforvaltning AB and Gulf International Bank UK Ltd. View Insider Buying and Selling for Pfizer. How do I buy shares of Pfizer? Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pfizer's stock price today? One share of PFE stock can currently be purchased for approximately $37.53. How big of a company is Pfizer? Pfizer has a market capitalization of $223.41 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe. How can I contact Pfizer? Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323. MarketBeat Community Rating for Pfizer (NYSE PFE)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 1,024 (Vote Outperform)Underperform Votes: 555 (Vote Underperform)Total Votes: 1,579MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What do I need to know about analyst ratings?